Aceso Life Science Group Income Statement

Financials in millions HKD. Fiscal year is April - March.

Millions HKD. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Total Interest Expense	114	124	143	140	154
Net Interest Income	-114	-124	-143	-140	-154
Other Revenue	58	195	228	312	315
Revenue Before Loan Losses	-56	71	85	172	161
Provision for Loan Losses	12	142	74	-35	-9
Revenue	-68	-71	11	207	170
Revenue Growth	-	-	-94.69%	21.77%	-
Cost of Services Provided	82	219	235	294	299
Total Operating Expenses	82	219	235	297	306
Operating Income	-150	-290	-224	-90	-136
Earnings From Equity Investments	-4	-94	-325	-209	-74
Currency Exchange Gain (Loss)	-2	-6	-4	12	9
EBT Excluding Unusual Items	-165	-378	-465	-193	-144
Gain (Loss) on Sale of Investments	-235	-29	-242	-81	-510
Other Unusual Items	-	-	-	60	9
Pretax Income	-421	-1,027	-823	-213	-555
Income Tax Expense	8	-10	-14	-5	41
Earnings From Continuing Ops.	-429	-1,017	-809	-208	-596
Earnings From Discontinued Ops.	767	-	-	-	-
Net Income to Company	338	-1,017	-809	-208	-596
Minority Interest in Earnings	-	122	347	-56	226
Net Income	338	-895	-462	-264	-370
Net Income to Common	338	-895	-462	-264	-370
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	7,440	7,197	7,274	7,318	7,203
Shares Outstanding (Diluted)	7,440	7,197	7,274	7,318	7,439
Shares Change	3.38%	-1.06%	-0.60%	-1.63%	6.06%
EPS (Basic)	0.05	-0.12	-0.06	-0.04	-0.05
EPS (Diluted)	0.05	-0.12	-0.06	-0.04	-0.06
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Free Cash Flow	-	15	-48	190	259
Free Cash Flow Per Share	-	0.00	-0.01	0.03	0.04
Operating Margin	-	-	-2036.36%	-43.48%	-80.00%
Profit Margin	-	-	-4200.00%	-127.54%	-217.65%
Free Cash Flow Margin	-	-	-436.36%	91.79%	152.35%